Investigational drug · Phase 3
QRX-3
Also called: Eseronate
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "QRX-3"
First trial start
2025
Oct 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QRX-3", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Kidney Diseases
- Acute Kidney Injury
- Kidney Failure
- Acute Renal Failure (ARF)
- Acute Tubular Necrosis
Approved drugs for the same conditions: Chronic kidney disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "QRX-3" as an intervention, largest first.
- Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease ProgressionPivotal-lookingNot yet recruiting
Ebima Clifford OkundayeIndustry
NCT06866236 · 3,000 participants (planned) · Start Oct 2025 · Primary completion Oct 2026
Drug: QRX-3 · For: Chronic Kidney Diseases; Acute Kidney Injury; Kidney Failure
Sites: Pasedena, Texas
- Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)Pivotal-lookingNot yet recruiting
Ebima Clifford OkundayeIndustry
NCT07161843 · 500 participants (planned) · Start Jun 30, 2026 · Primary completion Dec 30, 2026
Drug: QRX-3 · For: Acute Renal Failure (ARF); Acute Tubular Necrosis
Sites: Rosharon, Texas
Ebima Clifford OkundayeIndustry
NCT06948292 · 127 participants · Start Mar 1, 2023 · Primary completion Aug 30, 2024
Drug: QRX-3 · For: Chronic Kidney Disease Stages 3-5; Diabetic Kidney Disease; Hypertensive Kidney Disease
Sites: Pasedena, Texas
Neukidney Inc.Industry
NCT07150338 · 45 participants · Start May 20, 2021 · Primary completion Apr 20, 2022
Drug: QRX-3; Eseronate · For: Chronic Kidney Disease (Stage 3-4); Chronic Kidney Disease (Stages 4 and 5); Proteinuria
Sites: Pasadena, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Kidney Diseases
- PacibekitugTOUR006, PAC001Phase 33 trials
Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases
- rilparencelRenal Autologous Cell Therapy, REACTPhase 32 trials
Prokidney · Type 2 Diabetes Mellitus, Chronic Kidney Diseases, Type 1 Diabetes Mellitus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.